nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—TYMS—ovarian cancer	0.597	1	CbGaD
Pemetrexed—GART—myometrium—ovarian cancer	0.00407	0.0406	CbGeAlD
Pemetrexed—GART—uterine cervix—ovarian cancer	0.00317	0.0316	CbGeAlD
Pemetrexed—GART—decidua—ovarian cancer	0.00302	0.0301	CbGeAlD
Pemetrexed—GART—endometrium—ovarian cancer	0.00286	0.0286	CbGeAlD
Pemetrexed—ATIC—embryo—ovarian cancer	0.00266	0.0265	CbGeAlD
Pemetrexed—GART—gonad—ovarian cancer	0.00266	0.0265	CbGeAlD
Pemetrexed—SLC46A1—decidua—ovarian cancer	0.00245	0.0244	CbGeAlD
Pemetrexed—GART—female reproductive system—ovarian cancer	0.00237	0.0237	CbGeAlD
Pemetrexed—Methotrexate—FOLR1—ovarian cancer	0.00234	0.341	CrCbGaD
Pemetrexed—GART—bone marrow—ovarian cancer	0.00224	0.0223	CbGeAlD
Pemetrexed—ATIC—epithelium—ovarian cancer	0.00217	0.0216	CbGeAlD
Pemetrexed—GART—female gonad—ovarian cancer	0.00216	0.0215	CbGeAlD
Pemetrexed—GART—vagina—ovarian cancer	0.00215	0.0214	CbGeAlD
Pemetrexed—GART—testis—ovarian cancer	0.00192	0.0191	CbGeAlD
Pemetrexed—DHFR—myometrium—ovarian cancer	0.00186	0.0185	CbGeAlD
Pemetrexed—ATIC—gonad—ovarian cancer	0.0018	0.018	CbGeAlD
Pemetrexed—ATIC—uterus—ovarian cancer	0.00179	0.0179	CbGeAlD
Pemetrexed—DHFR—embryo—ovarian cancer	0.00179	0.0178	CbGeAlD
Pemetrexed—SLC46A1—female gonad—ovarian cancer	0.00175	0.0175	CbGeAlD
Pemetrexed—SLC29A1—myometrium—ovarian cancer	0.00168	0.0168	CbGeAlD
Pemetrexed—TYMS—Docetaxel—Paclitaxel—ovarian cancer	0.00164	0.393	CbGdCrCtD
Pemetrexed—ATIC—female reproductive system—ovarian cancer	0.00161	0.0161	CbGeAlD
Pemetrexed—DCK—myometrium—ovarian cancer	0.00161	0.016	CbGeAlD
Pemetrexed—SLC46A1—testis—ovarian cancer	0.00155	0.0155	CbGeAlD
Pemetrexed—DCK—embryo—ovarian cancer	0.00154	0.0154	CbGeAlD
Pemetrexed—Raltitrexed—TYMS—ovarian cancer	0.00154	0.225	CrCbGaD
Pemetrexed—ATIC—female gonad—ovarian cancer	0.00147	0.0146	CbGeAlD
Pemetrexed—TYMS—uterine cervix—ovarian cancer	0.00146	0.0145	CbGeAlD
Pemetrexed—DHFR—uterine cervix—ovarian cancer	0.00144	0.0144	CbGeAlD
Pemetrexed—GART—lymph node—ovarian cancer	0.00139	0.0138	CbGeAlD
Pemetrexed—DHFR—decidua—ovarian cancer	0.00138	0.0137	CbGeAlD
Pemetrexed—TYMS—endometrium—ovarian cancer	0.00132	0.0132	CbGeAlD
Pemetrexed—SLC29A1—uterine cervix—ovarian cancer	0.00131	0.013	CbGeAlD
Pemetrexed—DHFR—endometrium—ovarian cancer	0.00131	0.013	CbGeAlD
Pemetrexed—ATIC—testis—ovarian cancer	0.0013	0.013	CbGeAlD
Pemetrexed—DCK—uterine cervix—ovarian cancer	0.00125	0.0125	CbGeAlD
Pemetrexed—SLC29A1—decidua—ovarian cancer	0.00125	0.0124	CbGeAlD
Pemetrexed—TYMS—gonad—ovarian cancer	0.00122	0.0122	CbGeAlD
Pemetrexed—DHFR—gonad—ovarian cancer	0.00121	0.0121	CbGeAlD
Pemetrexed—DHFR—uterus—ovarian cancer	0.0012	0.012	CbGeAlD
Pemetrexed—DCK—decidua—ovarian cancer	0.00119	0.0119	CbGeAlD
Pemetrexed—SLC29A1—endometrium—ovarian cancer	0.00118	0.0118	CbGeAlD
Pemetrexed—Leucovorin—TYMS—ovarian cancer	0.00117	0.17	CrCbGaD
Pemetrexed—Pralatrexate—TYMS—ovarian cancer	0.00117	0.17	CrCbGaD
Pemetrexed—DCK—endometrium—ovarian cancer	0.00113	0.0113	CbGeAlD
Pemetrexed—SLC46A1—lymph node—ovarian cancer	0.00113	0.0112	CbGeAlD
Pemetrexed—SLC29A1—gonad—ovarian cancer	0.0011	0.0109	CbGeAlD
Pemetrexed—TYMS—female reproductive system—ovarian cancer	0.00109	0.0109	CbGeAlD
Pemetrexed—SLC29A1—uterus—ovarian cancer	0.00109	0.0109	CbGeAlD
Pemetrexed—DHFR—female reproductive system—ovarian cancer	0.00108	0.0108	CbGeAlD
Pemetrexed—DCK—gonad—ovarian cancer	0.00105	0.0105	CbGeAlD
Pemetrexed—DCK—uterus—ovarian cancer	0.00104	0.0104	CbGeAlD
Pemetrexed—TYMS—bone marrow—ovarian cancer	0.00103	0.0103	CbGeAlD
Pemetrexed—DHFR—bone marrow—ovarian cancer	0.00102	0.0102	CbGeAlD
Pemetrexed—TYMS—female gonad—ovarian cancer	0.000995	0.00992	CbGeAlD
Pemetrexed—TYMS—vagina—ovarian cancer	0.000988	0.00986	CbGeAlD
Pemetrexed—DHFR—female gonad—ovarian cancer	0.000985	0.00982	CbGeAlD
Pemetrexed—SLC29A1—female reproductive system—ovarian cancer	0.00098	0.00977	CbGeAlD
Pemetrexed—DHFR—vagina—ovarian cancer	0.000979	0.00976	CbGeAlD
Pemetrexed—ATIC—lymph node—ovarian cancer	0.000943	0.0094	CbGeAlD
Pemetrexed—DCK—female reproductive system—ovarian cancer	0.000936	0.00933	CbGeAlD
Pemetrexed—SLC29A1—bone marrow—ovarian cancer	0.000925	0.00923	CbGeAlD
Pemetrexed—SLC29A1—female gonad—ovarian cancer	0.000892	0.00889	CbGeAlD
Pemetrexed—SLC29A1—vagina—ovarian cancer	0.000886	0.00884	CbGeAlD
Pemetrexed—DCK—bone marrow—ovarian cancer	0.000884	0.00881	CbGeAlD
Pemetrexed—TYMS—testis—ovarian cancer	0.000882	0.00879	CbGeAlD
Pemetrexed—DHFR—testis—ovarian cancer	0.000873	0.00871	CbGeAlD
Pemetrexed—DCK—female gonad—ovarian cancer	0.000852	0.00849	CbGeAlD
Pemetrexed—DCK—vagina—ovarian cancer	0.000847	0.00844	CbGeAlD
Pemetrexed—TYMS—Paclitaxel—Docetaxel—ovarian cancer	0.000818	0.196	CbGdCrCtD
Pemetrexed—SLC29A1—testis—ovarian cancer	0.000791	0.00789	CbGeAlD
Pemetrexed—DCK—testis—ovarian cancer	0.000756	0.00753	CbGeAlD
Pemetrexed—TYMS—lymph node—ovarian cancer	0.000639	0.00637	CbGeAlD
Pemetrexed—DHFR—lymph node—ovarian cancer	0.000633	0.00631	CbGeAlD
Pemetrexed—SLC29A1—lymph node—ovarian cancer	0.000573	0.00572	CbGeAlD
Pemetrexed—TYMS—Vincristine—Vinorelbine—ovarian cancer	0.000562	0.135	CbGdCrCtD
Pemetrexed—DCK—lymph node—ovarian cancer	0.000548	0.00546	CbGeAlD
Pemetrexed—Methotrexate—TYMS—ovarian cancer	0.000514	0.075	CrCbGaD
Pemetrexed—TYMS—Vinblastine—Vinorelbine—ovarian cancer	0.000452	0.108	CbGdCrCtD
Pemetrexed—DCK—Doxorubicin—Epirubicin—ovarian cancer	0.000364	0.0872	CbGdCrCtD
Pemetrexed—DCK—Epirubicin—Doxorubicin—ovarian cancer	0.000337	0.0807	CbGdCrCtD
Pemetrexed—Diarrhoea—Topotecan—ovarian cancer	0.00017	0.000889	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Epirubicin—ovarian cancer	0.00017	0.000888	CcSEcCtD
Pemetrexed—Pharyngitis—Docetaxel—ovarian cancer	0.000169	0.000885	CcSEcCtD
Pemetrexed—Urticaria—Vinorelbine—ovarian cancer	0.000169	0.000883	CcSEcCtD
Pemetrexed—Urinary tract disorder—Docetaxel—ovarian cancer	0.000168	0.000881	CcSEcCtD
Pemetrexed—Abdominal pain—Vinorelbine—ovarian cancer	0.000168	0.000879	CcSEcCtD
Pemetrexed—Body temperature increased—Vinorelbine—ovarian cancer	0.000168	0.000879	CcSEcCtD
Pemetrexed—Urethral disorder—Docetaxel—ovarian cancer	0.000167	0.000874	CcSEcCtD
Pemetrexed—Renal failure acute—Doxorubicin—ovarian cancer	0.000167	0.000872	CcSEcCtD
Pemetrexed—Diarrhoea—Melphalan—ovarian cancer	0.000166	0.000871	CcSEcCtD
Pemetrexed—Nausea—Chlorambucil—ovarian cancer	0.000166	0.000867	CcSEcCtD
Pemetrexed—Dizziness—Topotecan—ovarian cancer	0.000164	0.000859	CcSEcCtD
Pemetrexed—Anaemia—Paclitaxel—ovarian cancer	0.000162	0.000847	CcSEcCtD
Pemetrexed—Erythema multiforme—Docetaxel—ovarian cancer	0.000161	0.000843	CcSEcCtD
Pemetrexed—Eye disorder—Docetaxel—ovarian cancer	0.000159	0.000834	CcSEcCtD
Pemetrexed—Vomiting—Topotecan—ovarian cancer	0.000158	0.000826	CcSEcCtD
Pemetrexed—Mood swings—Epirubicin—ovarian cancer	0.000157	0.000824	CcSEcCtD
Pemetrexed—Syncope—Paclitaxel—ovarian cancer	0.000157	0.000822	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.000157	0.000821	CcSEcCtD
Pemetrexed—Leukopenia—Paclitaxel—ovarian cancer	0.000157	0.00082	CcSEcCtD
Pemetrexed—Rash—Topotecan—ovarian cancer	0.000157	0.000819	CcSEcCtD
Pemetrexed—Hypersensitivity—Vinorelbine—ovarian cancer	0.000157	0.000819	CcSEcCtD
Pemetrexed—Dermatitis—Topotecan—ovarian cancer	0.000156	0.000819	CcSEcCtD
Pemetrexed—Blood creatinine increased—Epirubicin—ovarian cancer	0.000156	0.000815	CcSEcCtD
Pemetrexed—Vomiting—Melphalan—ovarian cancer	0.000155	0.000809	CcSEcCtD
Pemetrexed—Dehydration—Epirubicin—ovarian cancer	0.000155	0.000809	CcSEcCtD
Pemetrexed—Loss of consciousness—Paclitaxel—ovarian cancer	0.000154	0.000805	CcSEcCtD
Pemetrexed—Rash—Melphalan—ovarian cancer	0.000153	0.000802	CcSEcCtD
Pemetrexed—Dermatitis—Melphalan—ovarian cancer	0.000153	0.000802	CcSEcCtD
Pemetrexed—Asthenia—Vinorelbine—ovarian cancer	0.000152	0.000798	CcSEcCtD
Pemetrexed—Arrhythmia—Docetaxel—ovarian cancer	0.000152	0.000797	CcSEcCtD
Pemetrexed—Hypertension—Paclitaxel—ovarian cancer	0.000151	0.000791	CcSEcCtD
Pemetrexed—Alopecia—Docetaxel—ovarian cancer	0.000151	0.000788	CcSEcCtD
Pemetrexed—Pruritus—Vinorelbine—ovarian cancer	0.00015	0.000786	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.00015	0.000783	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.00015	0.000783	CcSEcCtD
Pemetrexed—Arthralgia—Paclitaxel—ovarian cancer	0.000149	0.00078	CcSEcCtD
Pemetrexed—Chest pain—Paclitaxel—ovarian cancer	0.000149	0.00078	CcSEcCtD
Pemetrexed—Myalgia—Paclitaxel—ovarian cancer	0.000149	0.00078	CcSEcCtD
Pemetrexed—Erythema—Docetaxel—ovarian cancer	0.000148	0.000777	CcSEcCtD
Pemetrexed—Malnutrition—Docetaxel—ovarian cancer	0.000148	0.000777	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000148	0.000775	CcSEcCtD
Pemetrexed—Nausea—Topotecan—ovarian cancer	0.000147	0.000772	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000147	0.000767	CcSEcCtD
Pemetrexed—Mood swings—Doxorubicin—ovarian cancer	0.000146	0.000762	CcSEcCtD
Pemetrexed—Diarrhoea—Vinorelbine—ovarian cancer	0.000145	0.000761	CcSEcCtD
Pemetrexed—Dysgeusia—Docetaxel—ovarian cancer	0.000145	0.00076	CcSEcCtD
Pemetrexed—Nausea—Melphalan—ovarian cancer	0.000144	0.000756	CcSEcCtD
Pemetrexed—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000144	0.000754	CcSEcCtD
Pemetrexed—Dysphagia—Epirubicin—ovarian cancer	0.000144	0.000752	CcSEcCtD
Pemetrexed—Dehydration—Doxorubicin—ovarian cancer	0.000143	0.000748	CcSEcCtD
Pemetrexed—Oedema—Paclitaxel—ovarian cancer	0.000143	0.000748	CcSEcCtD
Pemetrexed—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000143	0.000748	CcSEcCtD
Pemetrexed—Infection—Paclitaxel—ovarian cancer	0.000142	0.000743	CcSEcCtD
Pemetrexed—Pancreatitis—Epirubicin—ovarian cancer	0.000141	0.000737	CcSEcCtD
Pemetrexed—Shock—Paclitaxel—ovarian cancer	0.000141	0.000736	CcSEcCtD
Pemetrexed—Dizziness—Vinorelbine—ovarian cancer	0.00014	0.000735	CcSEcCtD
Pemetrexed—Nervous system disorder—Paclitaxel—ovarian cancer	0.00014	0.000733	CcSEcCtD
Pemetrexed—Angina pectoris—Epirubicin—ovarian cancer	0.00014	0.000732	CcSEcCtD
Pemetrexed—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00014	0.000732	CcSEcCtD
Pemetrexed—Skin disorder—Paclitaxel—ovarian cancer	0.000139	0.000726	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000138	0.000725	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000138	0.000725	CcSEcCtD
Pemetrexed—Anaemia—Docetaxel—ovarian cancer	0.000137	0.000718	CcSEcCtD
Pemetrexed—Pancytopenia—Epirubicin—ovarian cancer	0.000136	0.000714	CcSEcCtD
Pemetrexed—Anorexia—Paclitaxel—ovarian cancer	0.000136	0.000713	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000136	0.00071	CcSEcCtD
Pemetrexed—Vomiting—Vinorelbine—ovarian cancer	0.000135	0.000707	CcSEcCtD
Pemetrexed—Neutropenia—Epirubicin—ovarian cancer	0.000134	0.000703	CcSEcCtD
Pemetrexed—Rash—Vinorelbine—ovarian cancer	0.000134	0.000701	CcSEcCtD
Pemetrexed—Dermatitis—Vinorelbine—ovarian cancer	0.000134	0.0007	CcSEcCtD
Pemetrexed—Syncope—Docetaxel—ovarian cancer	0.000133	0.000696	CcSEcCtD
Pemetrexed—Dysphagia—Doxorubicin—ovarian cancer	0.000133	0.000696	CcSEcCtD
Pemetrexed—Leukopenia—Docetaxel—ovarian cancer	0.000133	0.000695	CcSEcCtD
Pemetrexed—Loss of consciousness—Docetaxel—ovarian cancer	0.00013	0.000683	CcSEcCtD
Pemetrexed—Pancreatitis—Doxorubicin—ovarian cancer	0.00013	0.000682	CcSEcCtD
Pemetrexed—Methotrexate—ABCB1—ovarian cancer	0.00013	0.019	CrCbGaD
Pemetrexed—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00013	0.000681	CcSEcCtD
Pemetrexed—Angina pectoris—Doxorubicin—ovarian cancer	0.000129	0.000678	CcSEcCtD
Pemetrexed—Hypertension—Docetaxel—ovarian cancer	0.000128	0.00067	CcSEcCtD
Pemetrexed—Infestation NOS—Epirubicin—ovarian cancer	0.000128	0.00067	CcSEcCtD
Pemetrexed—Infestation—Epirubicin—ovarian cancer	0.000128	0.00067	CcSEcCtD
Pemetrexed—Dyspnoea—Paclitaxel—ovarian cancer	0.000127	0.000667	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000127	0.000664	CcSEcCtD
Pemetrexed—Chest pain—Docetaxel—ovarian cancer	0.000126	0.000661	CcSEcCtD
Pemetrexed—Arthralgia—Docetaxel—ovarian cancer	0.000126	0.000661	CcSEcCtD
Pemetrexed—Myalgia—Docetaxel—ovarian cancer	0.000126	0.000661	CcSEcCtD
Pemetrexed—Pancytopenia—Doxorubicin—ovarian cancer	0.000126	0.000661	CcSEcCtD
Pemetrexed—Nausea—Vinorelbine—ovarian cancer	0.000126	0.00066	CcSEcCtD
Pemetrexed—Renal failure—Epirubicin—ovarian cancer	0.000126	0.000659	CcSEcCtD
Pemetrexed—Dyspepsia—Paclitaxel—ovarian cancer	0.000126	0.000658	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000126	0.000657	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000125	0.000657	CcSEcCtD
Pemetrexed—SLC46A1—Disease—HDAC6—ovarian cancer	0.000125	0.00125	CbGpPWpGaD
Pemetrexed—Stomatitis—Epirubicin—ovarian cancer	0.000125	0.000653	CcSEcCtD
Pemetrexed—Conjunctivitis—Epirubicin—ovarian cancer	0.000124	0.000651	CcSEcCtD
Pemetrexed—DHFR—Folate Metabolism—TP53—ovarian cancer	0.000124	0.00124	CbGpPWpGaD
Pemetrexed—Neutropenia—Doxorubicin—ovarian cancer	0.000124	0.00065	CcSEcCtD
Pemetrexed—Decreased appetite—Paclitaxel—ovarian cancer	0.000124	0.00065	CcSEcCtD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	0.000124	0.00124	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000123	0.000646	CcSEcCtD
Pemetrexed—Fatigue—Paclitaxel—ovarian cancer	0.000123	0.000645	CcSEcCtD
Pemetrexed—Pain—Paclitaxel—ovarian cancer	0.000122	0.000639	CcSEcCtD
Pemetrexed—Constipation—Paclitaxel—ovarian cancer	0.000122	0.000639	CcSEcCtD
Pemetrexed—TYMS—E2F transcription factor network—MYC—ovarian cancer	0.000122	0.00122	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.000121	0.00121	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	0.000121	0.00121	CbGpPWpGaD
Pemetrexed—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000121	0.000634	CcSEcCtD
Pemetrexed—Oedema—Docetaxel—ovarian cancer	0.000121	0.000634	CcSEcCtD
Pemetrexed—Anaphylactic shock—Docetaxel—ovarian cancer	0.000121	0.000634	CcSEcCtD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	0.000121	0.0012	CbGpPWpGaD
Pemetrexed—Infection—Docetaxel—ovarian cancer	0.00012	0.00063	CcSEcCtD
Pemetrexed—Agranulocytosis—Epirubicin—ovarian cancer	0.00012	0.000625	CcSEcCtD
Pemetrexed—Shock—Docetaxel—ovarian cancer	0.000119	0.000624	CcSEcCtD
Pemetrexed—DHFR—Disease—BCL9—ovarian cancer	0.000119	0.00119	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—YAP1—ovarian cancer	0.000119	0.00118	CbGpPWpGaD
Pemetrexed—Nervous system disorder—Docetaxel—ovarian cancer	0.000119	0.000622	CcSEcCtD
Pemetrexed—Thrombocytopenia—Docetaxel—ovarian cancer	0.000119	0.000621	CcSEcCtD
Pemetrexed—Infestation—Doxorubicin—ovarian cancer	0.000119	0.00062	CcSEcCtD
Pemetrexed—Infestation NOS—Doxorubicin—ovarian cancer	0.000119	0.00062	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—SKP2—ovarian cancer	0.000118	0.00117	CbGpPWpGaD
Pemetrexed—Skin disorder—Docetaxel—ovarian cancer	0.000118	0.000616	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000117	0.000615	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000117	0.000611	CcSEcCtD
Pemetrexed—Renal failure—Doxorubicin—ovarian cancer	0.000116	0.00061	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000116	0.000608	CcSEcCtD
Pemetrexed—TYMS—G1/S Transition—CDKN1B—ovarian cancer	0.000116	0.00115	CbGpPWpGaD
Pemetrexed—Stomatitis—Doxorubicin—ovarian cancer	0.000116	0.000605	CcSEcCtD
Pemetrexed—Anorexia—Docetaxel—ovarian cancer	0.000115	0.000604	CcSEcCtD
Pemetrexed—Conjunctivitis—Doxorubicin—ovarian cancer	0.000115	0.000603	CcSEcCtD
Pemetrexed—Hepatitis—Epirubicin—ovarian cancer	0.000115	0.000602	CcSEcCtD
Pemetrexed—TYMS—Metabolism—NME2—ovarian cancer	0.000115	0.00114	CbGpPWpGaD
Pemetrexed—Pharyngitis—Epirubicin—ovarian cancer	0.000114	0.000597	CcSEcCtD
Pemetrexed—DHFR—Folate Metabolism—IL6—ovarian cancer	0.000114	0.00114	CbGpPWpGaD
Pemetrexed—Urinary tract disorder—Epirubicin—ovarian cancer	0.000114	0.000594	CcSEcCtD
Pemetrexed—Urticaria—Paclitaxel—ovarian cancer	0.000114	0.000594	CcSEcCtD
Pemetrexed—Body temperature increased—Paclitaxel—ovarian cancer	0.000113	0.000591	CcSEcCtD
Pemetrexed—Abdominal pain—Paclitaxel—ovarian cancer	0.000113	0.000591	CcSEcCtD
Pemetrexed—GART—Metabolism—PPP2R1A—ovarian cancer	0.000113	0.00113	CbGpPWpGaD
Pemetrexed—Urethral disorder—Epirubicin—ovarian cancer	0.000113	0.00059	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000112	0.000587	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CDKN1B—ovarian cancer	0.000112	0.00111	CbGpPWpGaD
Pemetrexed—Agranulocytosis—Doxorubicin—ovarian cancer	0.000111	0.000579	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00011	0.000577	CcSEcCtD
Pemetrexed—Erythema multiforme—Epirubicin—ovarian cancer	0.000109	0.000569	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000109	0.00108	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—XIAP—ovarian cancer	0.000108	0.00108	CbGpPWpGaD
Pemetrexed—Dyspnoea—Docetaxel—ovarian cancer	0.000108	0.000565	CcSEcCtD
Pemetrexed—Eye disorder—Epirubicin—ovarian cancer	0.000107	0.000562	CcSEcCtD
Pemetrexed—Dyspepsia—Docetaxel—ovarian cancer	0.000107	0.000558	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CCND1—ovarian cancer	0.000107	0.00106	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MLH1—ovarian cancer	0.000106	0.00106	CbGpPWpGaD
Pemetrexed—Hepatitis—Doxorubicin—ovarian cancer	0.000106	0.000557	CcSEcCtD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.000106	0.00106	CbGpPWpGaD
Pemetrexed—Pharyngitis—Doxorubicin—ovarian cancer	0.000106	0.000553	CcSEcCtD
Pemetrexed—SLC46A1—Disease—SMARCA4—ovarian cancer	0.000106	0.00105	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYTB—ovarian cancer	0.000105	0.00105	CbGpPWpGaD
Pemetrexed—Decreased appetite—Docetaxel—ovarian cancer	0.000105	0.000551	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—SKP2—ovarian cancer	0.000105	0.00105	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Paclitaxel—ovarian cancer	0.000105	0.000551	CcSEcCtD
Pemetrexed—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000105	0.00055	CcSEcCtD
Pemetrexed—GART—Metabolism—ABCB1—ovarian cancer	0.000105	0.00104	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000105	0.000547	CcSEcCtD
Pemetrexed—Fatigue—Docetaxel—ovarian cancer	0.000104	0.000546	CcSEcCtD
Pemetrexed—Urethral disorder—Doxorubicin—ovarian cancer	0.000104	0.000546	CcSEcCtD
Pemetrexed—Constipation—Docetaxel—ovarian cancer	0.000104	0.000542	CcSEcCtD
Pemetrexed—Pain—Docetaxel—ovarian cancer	0.000104	0.000542	CcSEcCtD
Pemetrexed—SLC46A1—Disease—EREG—ovarian cancer	0.000103	0.00103	CbGpPWpGaD
Pemetrexed—GART—Metabolism—TYMS—ovarian cancer	0.000103	0.00103	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—SKP2—ovarian cancer	0.000103	0.00102	CbGpPWpGaD
Pemetrexed—Arrhythmia—Epirubicin—ovarian cancer	0.000103	0.000538	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000103	0.00102	CbGpPWpGaD
Pemetrexed—Asthenia—Paclitaxel—ovarian cancer	0.000103	0.000536	CcSEcCtD
Pemetrexed—Alopecia—Epirubicin—ovarian cancer	0.000102	0.000532	CcSEcCtD
Pemetrexed—DHFR—G1/S Transition—MYC—ovarian cancer	0.000101	0.00101	CbGpPWpGaD
Pemetrexed—Pruritus—Paclitaxel—ovarian cancer	0.000101	0.000529	CcSEcCtD
Pemetrexed—Erythema multiforme—Doxorubicin—ovarian cancer	0.000101	0.000526	CcSEcCtD
Pemetrexed—Erythema—Epirubicin—ovarian cancer	0.0001	0.000524	CcSEcCtD
Pemetrexed—Malnutrition—Epirubicin—ovarian cancer	0.0001	0.000524	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	9.98e-05	0.000994	CbGpPWpGaD
Pemetrexed—Eye disorder—Doxorubicin—ovarian cancer	9.94e-05	0.00052	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Docetaxel—ovarian cancer	9.9e-05	0.000518	CcSEcCtD
Pemetrexed—Dysgeusia—Epirubicin—ovarian cancer	9.8e-05	0.000513	CcSEcCtD
Pemetrexed—Diarrhoea—Paclitaxel—ovarian cancer	9.78e-05	0.000512	CcSEcCtD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDKN1B—ovarian cancer	9.75e-05	0.000971	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—FASN—ovarian cancer	9.69e-05	0.000966	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	9.59e-05	0.000955	CbGpPWpGaD
Pemetrexed—Body temperature increased—Docetaxel—ovarian cancer	9.57e-05	0.000501	CcSEcCtD
Pemetrexed—Abdominal pain—Docetaxel—ovarian cancer	9.57e-05	0.000501	CcSEcCtD
Pemetrexed—ATIC—Metabolism—SLC5A5—ovarian cancer	9.53e-05	0.00095	CbGpPWpGaD
Pemetrexed—Arrhythmia—Doxorubicin—ovarian cancer	9.5e-05	0.000497	CcSEcCtD
Pemetrexed—Dizziness—Paclitaxel—ovarian cancer	9.45e-05	0.000494	CcSEcCtD
Pemetrexed—Alopecia—Doxorubicin—ovarian cancer	9.4e-05	0.000492	CcSEcCtD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CCND1—ovarian cancer	9.3e-05	0.000927	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MLH1—ovarian cancer	9.29e-05	0.000926	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—YAP1—ovarian cancer	9.26e-05	0.000923	CbGpPWpGaD
Pemetrexed—Malnutrition—Doxorubicin—ovarian cancer	9.26e-05	0.000485	CcSEcCtD
Pemetrexed—Erythema—Doxorubicin—ovarian cancer	9.26e-05	0.000485	CcSEcCtD
Pemetrexed—Anaemia—Epirubicin—ovarian cancer	9.25e-05	0.000484	CcSEcCtD
Pemetrexed—DCK—Metabolism—BRIP1—ovarian cancer	9.21e-05	0.000918	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PPP1CC—ovarian cancer	9.21e-05	0.000918	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—SLC2A1—ovarian cancer	9.21e-05	0.000917	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—SKP2—ovarian cancer	9.19e-05	0.000915	CbGpPWpGaD
Pemetrexed—Vomiting—Paclitaxel—ovarian cancer	9.08e-05	0.000475	CcSEcCtD
Pemetrexed—Dysgeusia—Doxorubicin—ovarian cancer	9.07e-05	0.000475	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND2—ovarian cancer	9.02e-05	0.000899	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—FASN—ovarian cancer	9.01e-05	0.000898	CbGpPWpGaD
Pemetrexed—Rash—Paclitaxel—ovarian cancer	9.01e-05	0.000471	CcSEcCtD
Pemetrexed—Dermatitis—Paclitaxel—ovarian cancer	9e-05	0.000471	CcSEcCtD
Pemetrexed—SLC46A1—Disease—PARP1—ovarian cancer	8.98e-05	0.000895	CbGpPWpGaD
Pemetrexed—Syncope—Epirubicin—ovarian cancer	8.98e-05	0.00047	CcSEcCtD
Pemetrexed—Leukopenia—Epirubicin—ovarian cancer	8.96e-05	0.000469	CcSEcCtD
Pemetrexed—Hypersensitivity—Docetaxel—ovarian cancer	8.92e-05	0.000467	CcSEcCtD
Pemetrexed—TYMS—G1/S Transition—MYC—ovarian cancer	8.85e-05	0.000882	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PPP1CC—ovarian cancer	8.84e-05	0.000881	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—CYP1B1—ovarian cancer	8.83e-05	0.00088	CbGpPWpGaD
Pemetrexed—Loss of consciousness—Epirubicin—ovarian cancer	8.8e-05	0.00046	CcSEcCtD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	8.7e-05	0.000868	CbGpPWpGaD
Pemetrexed—Asthenia—Docetaxel—ovarian cancer	8.69e-05	0.000455	CcSEcCtD
Pemetrexed—Hypertension—Epirubicin—ovarian cancer	8.64e-05	0.000452	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—CHEK2—ovarian cancer	8.61e-05	0.000858	CbGpPWpGaD
Pemetrexed—Pruritus—Docetaxel—ovarian cancer	8.57e-05	0.000448	CcSEcCtD
Pemetrexed—SLC46A1—Disease—SLC2A1—ovarian cancer	8.56e-05	0.000853	CbGpPWpGaD
Pemetrexed—Anaemia—Doxorubicin—ovarian cancer	8.56e-05	0.000448	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—MYC—ovarian cancer	8.55e-05	0.000852	CbGpPWpGaD
Pemetrexed—Arthralgia—Epirubicin—ovarian cancer	8.52e-05	0.000446	CcSEcCtD
Pemetrexed—Myalgia—Epirubicin—ovarian cancer	8.52e-05	0.000446	CcSEcCtD
Pemetrexed—Chest pain—Epirubicin—ovarian cancer	8.52e-05	0.000446	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	8.51e-05	0.000848	CbGpPWpGaD
Pemetrexed—Nausea—Paclitaxel—ovarian cancer	8.49e-05	0.000444	CcSEcCtD
Pemetrexed—DHFR—Metabolism—CYTB—ovarian cancer	8.47e-05	0.000844	CbGpPWpGaD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	8.46e-05	0.000443	CcSEcCtD
Pemetrexed—Syncope—Doxorubicin—ovarian cancer	8.3e-05	0.000435	CcSEcCtD
Pemetrexed—GART—Metabolism—CAV1—ovarian cancer	8.3e-05	0.000827	CbGpPWpGaD
Pemetrexed—Leukopenia—Doxorubicin—ovarian cancer	8.29e-05	0.000434	CcSEcCtD
Pemetrexed—Diarrhoea—Docetaxel—ovarian cancer	8.29e-05	0.000434	CcSEcCtD
Pemetrexed—Oedema—Epirubicin—ovarian cancer	8.17e-05	0.000427	CcSEcCtD
Pemetrexed—Anaphylactic shock—Epirubicin—ovarian cancer	8.17e-05	0.000427	CcSEcCtD
Pemetrexed—Loss of consciousness—Doxorubicin—ovarian cancer	8.14e-05	0.000426	CcSEcCtD
Pemetrexed—Infection—Epirubicin—ovarian cancer	8.12e-05	0.000425	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—CCND2—ovarian cancer	8.07e-05	0.000804	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—BRCA1—ovarian cancer	8.07e-05	0.000804	CbGpPWpGaD
Pemetrexed—Shock—Epirubicin—ovarian cancer	8.04e-05	0.000421	CcSEcCtD
Pemetrexed—Nervous system disorder—Epirubicin—ovarian cancer	8.01e-05	0.000419	CcSEcCtD
Pemetrexed—Dizziness—Docetaxel—ovarian cancer	8.01e-05	0.000419	CcSEcCtD
Pemetrexed—Thrombocytopenia—Epirubicin—ovarian cancer	8e-05	0.000419	CcSEcCtD
Pemetrexed—Hypertension—Doxorubicin—ovarian cancer	8e-05	0.000418	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	7.97e-05	0.000795	CbGpPWpGaD
Pemetrexed—Skin disorder—Epirubicin—ovarian cancer	7.93e-05	0.000415	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCNE1—ovarian cancer	7.9e-05	0.000788	CbGpPWpGaD
Pemetrexed—Chest pain—Doxorubicin—ovarian cancer	7.88e-05	0.000413	CcSEcCtD
Pemetrexed—Arthralgia—Doxorubicin—ovarian cancer	7.88e-05	0.000413	CcSEcCtD
Pemetrexed—Myalgia—Doxorubicin—ovarian cancer	7.88e-05	0.000413	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND2—ovarian cancer	7.87e-05	0.000785	CbGpPWpGaD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	7.83e-05	0.00041	CcSEcCtD
Pemetrexed—ATIC—Metabolism—PPP2R1A—ovarian cancer	7.83e-05	0.00078	CbGpPWpGaD
Pemetrexed—Anorexia—Epirubicin—ovarian cancer	7.79e-05	0.000407	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—TYMS—ovarian cancer	7.76e-05	0.000774	CbGpPWpGaD
Pemetrexed—Vomiting—Docetaxel—ovarian cancer	7.7e-05	0.000403	CcSEcCtD
Pemetrexed—Rash—Docetaxel—ovarian cancer	7.64e-05	0.0004	CcSEcCtD
Pemetrexed—Dermatitis—Docetaxel—ovarian cancer	7.63e-05	0.000399	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—PPP2R1A—ovarian cancer	7.61e-05	0.000758	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CG—ovarian cancer	7.56e-05	0.000753	CbGpPWpGaD
Pemetrexed—Oedema—Doxorubicin—ovarian cancer	7.56e-05	0.000396	CcSEcCtD
Pemetrexed—Anaphylactic shock—Doxorubicin—ovarian cancer	7.56e-05	0.000396	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—FASN—ovarian cancer	7.55e-05	0.000752	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CHEK2—ovarian cancer	7.51e-05	0.000749	CbGpPWpGaD
Pemetrexed—Infection—Doxorubicin—ovarian cancer	7.51e-05	0.000393	CcSEcCtD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—MYC—ovarian cancer	7.46e-05	0.000743	CbGpPWpGaD
Pemetrexed—Musculoskeletal discomfort—Epirubicin—ovarian cancer	7.44e-05	0.000389	CcSEcCtD
Pemetrexed—Shock—Doxorubicin—ovarian cancer	7.44e-05	0.000389	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	7.43e-05	0.00074	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—SLC5A5—ovarian cancer	7.43e-05	0.00074	CbGpPWpGaD
Pemetrexed—Nervous system disorder—Doxorubicin—ovarian cancer	7.41e-05	0.000388	CcSEcCtD
Pemetrexed—DHFR—Metabolism—PPP1CC—ovarian cancer	7.4e-05	0.000738	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—BRIP1—ovarian cancer	7.4e-05	0.000738	CbGpPWpGaD
Pemetrexed—Thrombocytopenia—Doxorubicin—ovarian cancer	7.4e-05	0.000387	CcSEcCtD
Pemetrexed—TYMS—Metabolism—CYTB—ovarian cancer	7.39e-05	0.000737	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	7.38e-05	0.000736	CbGpPWpGaD
Pemetrexed—Skin disorder—Doxorubicin—ovarian cancer	7.34e-05	0.000384	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—BRCA2—ovarian cancer	7.3e-05	0.000727	CbGpPWpGaD
Pemetrexed—Dyspnoea—Epirubicin—ovarian cancer	7.28e-05	0.000381	CcSEcCtD
Pemetrexed—SLC46A1—Disease—PPP2R1A—ovarian cancer	7.28e-05	0.000726	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—ABCB1—ovarian cancer	7.27e-05	0.000724	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	7.24e-05	0.000721	CbGpPWpGaD
Pemetrexed—Anorexia—Doxorubicin—ovarian cancer	7.2e-05	0.000377	CcSEcCtD
Pemetrexed—Nausea—Docetaxel—ovarian cancer	7.19e-05	0.000376	CcSEcCtD
Pemetrexed—Dyspepsia—Epirubicin—ovarian cancer	7.19e-05	0.000376	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—SLC2A1—ovarian cancer	7.17e-05	0.000715	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—TYMS—ovarian cancer	7.14e-05	0.000711	CbGpPWpGaD
Pemetrexed—Decreased appetite—Epirubicin—ovarian cancer	7.1e-05	0.000372	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—CCNE1—ovarian cancer	7.07e-05	0.000704	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Epirubicin—ovarian cancer	7.05e-05	0.000369	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	7.04e-05	0.000702	CbGpPWpGaD
Pemetrexed—Fatigue—Epirubicin—ovarian cancer	7.04e-05	0.000369	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—CCND2—ovarian cancer	7.04e-05	0.000702	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—BRCA1—ovarian cancer	7.04e-05	0.000702	CbGpPWpGaD
Pemetrexed—Pain—Epirubicin—ovarian cancer	6.99e-05	0.000366	CcSEcCtD
Pemetrexed—Constipation—Epirubicin—ovarian cancer	6.99e-05	0.000366	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—BIRC5—ovarian cancer	6.98e-05	0.000696	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	6.98e-05	0.000695	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TYMS—ovarian cancer	6.94e-05	0.000692	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCNE1—ovarian cancer	6.9e-05	0.000687	CbGpPWpGaD
Pemetrexed—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	6.89e-05	0.00036	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—CYP1B1—ovarian cancer	6.88e-05	0.000685	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	6.8e-05	0.000678	CbGpPWpGaD
Pemetrexed—Dyspnoea—Doxorubicin—ovarian cancer	6.74e-05	0.000353	CcSEcCtD
Pemetrexed—DHFR—Disease—HDAC6—ovarian cancer	6.7e-05	0.000668	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Epirubicin—ovarian cancer	6.68e-05	0.00035	CcSEcCtD
Pemetrexed—Dyspepsia—Doxorubicin—ovarian cancer	6.65e-05	0.000348	CcSEcCtD
Pemetrexed—GART—Metabolism—PIK3CD—ovarian cancer	6.64e-05	0.000662	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—PPP2R1A—ovarian cancer	6.64e-05	0.000662	CbGpPWpGaD
Pemetrexed—Decreased appetite—Doxorubicin—ovarian cancer	6.57e-05	0.000344	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—PTEN—ovarian cancer	6.53e-05	0.000651	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Doxorubicin—ovarian cancer	6.53e-05	0.000341	CcSEcCtD
Pemetrexed—Fatigue—Doxorubicin—ovarian cancer	6.52e-05	0.000341	CcSEcCtD
Pemetrexed—Urticaria—Epirubicin—ovarian cancer	6.49e-05	0.00034	CcSEcCtD
Pemetrexed—Constipation—Doxorubicin—ovarian cancer	6.46e-05	0.000338	CcSEcCtD
Pemetrexed—Pain—Doxorubicin—ovarian cancer	6.46e-05	0.000338	CcSEcCtD
Pemetrexed—TYMS—Metabolism—PPP1CC—ovarian cancer	6.46e-05	0.000644	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—BRIP1—ovarian cancer	6.46e-05	0.000644	CbGpPWpGaD
Pemetrexed—Abdominal pain—Epirubicin—ovarian cancer	6.46e-05	0.000338	CcSEcCtD
Pemetrexed—Body temperature increased—Epirubicin—ovarian cancer	6.46e-05	0.000338	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—BRCA2—ovarian cancer	6.37e-05	0.000635	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—BIRC5—ovarian cancer	6.24e-05	0.000622	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Doxorubicin—ovarian cancer	6.18e-05	0.000323	CcSEcCtD
Pemetrexed—DCK—Metabolism—YAP1—ovarian cancer	6.18e-05	0.000616	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCNE1—ovarian cancer	6.17e-05	0.000615	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	6.14e-05	0.000612	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PPP2R1A—ovarian cancer	6.1e-05	0.000608	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—BIRC5—ovarian cancer	6.09e-05	0.000607	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TERT—ovarian cancer	6.05e-05	0.000603	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Epirubicin—ovarian cancer	6.02e-05	0.000315	CcSEcCtD
Pemetrexed—Urticaria—Doxorubicin—ovarian cancer	6e-05	0.000314	CcSEcCtD
Pemetrexed—Body temperature increased—Doxorubicin—ovarian cancer	5.97e-05	0.000313	CcSEcCtD
Pemetrexed—Abdominal pain—Doxorubicin—ovarian cancer	5.97e-05	0.000313	CcSEcCtD
Pemetrexed—Asthenia—Epirubicin—ovarian cancer	5.86e-05	0.000307	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	5.81e-05	0.000579	CbGpPWpGaD
Pemetrexed—DHFR—Disease—XIAP—ovarian cancer	5.81e-05	0.000579	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CB—ovarian cancer	5.79e-05	0.000577	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TERT—ovarian cancer	5.78e-05	0.000576	CbGpPWpGaD
Pemetrexed—Pruritus—Epirubicin—ovarian cancer	5.78e-05	0.000302	CcSEcCtD
Pemetrexed—ATIC—Metabolism—CAV1—ovarian cancer	5.75e-05	0.000573	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—ABCB1—ovarian cancer	5.66e-05	0.000564	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SMARCA4—ovarian cancer	5.66e-05	0.000564	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	5.65e-05	0.000563	CbGpPWpGaD
Pemetrexed—Diarrhoea—Epirubicin—ovarian cancer	5.59e-05	0.000292	CcSEcCtD
Pemetrexed—Hypersensitivity—Doxorubicin—ovarian cancer	5.57e-05	0.000291	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—TYMS—ovarian cancer	5.56e-05	0.000554	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	5.53e-05	0.000551	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	5.53e-05	0.000551	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EREG—ovarian cancer	5.53e-05	0.000551	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—BIRC5—ovarian cancer	5.45e-05	0.000543	CbGpPWpGaD
Pemetrexed—Asthenia—Doxorubicin—ovarian cancer	5.42e-05	0.000284	CcSEcCtD
Pemetrexed—Dizziness—Epirubicin—ovarian cancer	5.4e-05	0.000283	CcSEcCtD
Pemetrexed—SLC46A1—Disease—CAV1—ovarian cancer	5.35e-05	0.000533	CbGpPWpGaD
Pemetrexed—Pruritus—Doxorubicin—ovarian cancer	5.35e-05	0.00028	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—TERT—ovarian cancer	5.28e-05	0.000526	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CG—ovarian cancer	5.24e-05	0.000522	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	5.22e-05	0.00052	CbGpPWpGaD
Pemetrexed—Vomiting—Epirubicin—ovarian cancer	5.19e-05	0.000272	CcSEcCtD
Pemetrexed—Diarrhoea—Doxorubicin—ovarian cancer	5.17e-05	0.000271	CcSEcCtD
Pemetrexed—Rash—Epirubicin—ovarian cancer	5.15e-05	0.00027	CcSEcCtD
Pemetrexed—Dermatitis—Epirubicin—ovarian cancer	5.15e-05	0.000269	CcSEcCtD
Pemetrexed—SLC46A1—Disease—IL6ST—ovarian cancer	5.07e-05	0.000506	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—FASN—ovarian cancer	5.04e-05	0.000502	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PTEN—ovarian cancer	5e-05	0.000499	CbGpPWpGaD
Pemetrexed—Dizziness—Doxorubicin—ovarian cancer	5e-05	0.000262	CcSEcCtD
Pemetrexed—DHFR—Metabolism—YAP1—ovarian cancer	4.97e-05	0.000495	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—SLC5A5—ovarian cancer	4.95e-05	0.000494	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—APC—ovarian cancer	4.87e-05	0.000486	CbGpPWpGaD
Pemetrexed—Nausea—Epirubicin—ovarian cancer	4.85e-05	0.000254	CcSEcCtD
Pemetrexed—DHFR—Disease—FASN—ovarian cancer	4.83e-05	0.000482	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PARP1—ovarian cancer	4.81e-05	0.00048	CbGpPWpGaD
Pemetrexed—Vomiting—Doxorubicin—ovarian cancer	4.81e-05	0.000251	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	4.8e-05	0.000478	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—SLC2A1—ovarian cancer	4.79e-05	0.000477	CbGpPWpGaD
Pemetrexed—Rash—Doxorubicin—ovarian cancer	4.77e-05	0.000249	CcSEcCtD
Pemetrexed—Dermatitis—Doxorubicin—ovarian cancer	4.76e-05	0.000249	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	4.64e-05	0.000462	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CD—ovarian cancer	4.61e-05	0.000459	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SLC2A1—ovarian cancer	4.59e-05	0.000458	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP1B1—ovarian cancer	4.59e-05	0.000457	CbGpPWpGaD
Pemetrexed—Nausea—Doxorubicin—ovarian cancer	4.49e-05	0.000235	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—CAV1—ovarian cancer	4.48e-05	0.000447	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—TP53—ovarian cancer	4.45e-05	0.000444	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—YAP1—ovarian cancer	4.33e-05	0.000432	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CD—ovarian cancer	4.28e-05	0.000427	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	4.1e-05	0.000408	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CG—ovarian cancer	4.08e-05	0.000407	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—IL6—ovarian cancer	4.08e-05	0.000406	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PPP2R1A—ovarian cancer	4.07e-05	0.000405	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—FASN—ovarian cancer	4.05e-05	0.000403	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CB—ovarian cancer	4.01e-05	0.0004	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—SLC5A5—ovarian cancer	3.98e-05	0.000397	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	3.92e-05	0.000391	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND1—ovarian cancer	3.91e-05	0.000389	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PPP2R1A—ovarian cancer	3.9e-05	0.000389	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—SLC2A1—ovarian cancer	3.85e-05	0.000383	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—ERBB2—ovarian cancer	3.78e-05	0.000377	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ABCB1—ovarian cancer	3.78e-05	0.000377	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MTOR—ovarian cancer	3.73e-05	0.000372	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CB—ovarian cancer	3.73e-05	0.000372	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—TYMS—ovarian cancer	3.71e-05	0.00037	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP1B1—ovarian cancer	3.69e-05	0.000367	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN1B—ovarian cancer	3.66e-05	0.000365	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CD—ovarian cancer	3.59e-05	0.000358	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	3.57e-05	0.000356	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—FASN—ovarian cancer	3.53e-05	0.000352	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CA—ovarian cancer	3.53e-05	0.000352	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN1B—ovarian cancer	3.5e-05	0.000349	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND1—ovarian cancer	3.49e-05	0.000348	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SLC5A5—ovarian cancer	3.47e-05	0.000346	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTEN—ovarian cancer	3.47e-05	0.000346	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND1—ovarian cancer	3.41e-05	0.00034	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SLC2A1—ovarian cancer	3.36e-05	0.000334	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CTNNB1—ovarian cancer	3.31e-05	0.00033	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PPP2R1A—ovarian cancer	3.27e-05	0.000326	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTEN—ovarian cancer	3.23e-05	0.000322	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MAPK3—ovarian cancer	3.22e-05	0.000321	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP1B1—ovarian cancer	3.22e-05	0.000321	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN1B—ovarian cancer	3.2e-05	0.000319	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MYC—ovarian cancer	3.13e-05	0.000312	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CB—ovarian cancer	3.13e-05	0.000312	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TERT—ovarian cancer	3.1e-05	0.000309	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MAPK1—ovarian cancer	3.07e-05	0.000306	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND1—ovarian cancer	3.05e-05	0.000304	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ABCB1—ovarian cancer	3.04e-05	0.000303	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CAV1—ovarian cancer	2.99e-05	0.000298	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—TYMS—ovarian cancer	2.98e-05	0.000297	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—STAT3—ovarian cancer	2.89e-05	0.000288	CbGpPWpGaD
Pemetrexed—GART—Metabolism—AKT1—ovarian cancer	2.88e-05	0.000287	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MAPK3—ovarian cancer	2.88e-05	0.000287	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NRAS—ovarian cancer	2.88e-05	0.000287	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CAV1—ovarian cancer	2.87e-05	0.000286	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PPP2R1A—ovarian cancer	2.85e-05	0.000284	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MAPK3—ovarian cancer	2.81e-05	0.00028	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MYC—ovarian cancer	2.8e-05	0.000279	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MAPK3—ovarian cancer	2.76e-05	0.000275	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MAPK1—ovarian cancer	2.74e-05	0.000273	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MYC—ovarian cancer	2.74e-05	0.000273	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CG—ovarian cancer	2.72e-05	0.000271	CbGpPWpGaD
Pemetrexed—DHFR—Disease—IL6ST—ovarian cancer	2.72e-05	0.000271	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTEN—ovarian cancer	2.7e-05	0.000269	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MYC—ovarian cancer	2.68e-05	0.000267	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MAPK1—ovarian cancer	2.68e-05	0.000267	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ABCB1—ovarian cancer	2.65e-05	0.000264	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MAPK1—ovarian cancer	2.62e-05	0.000261	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EGFR—ovarian cancer	2.62e-05	0.000261	CbGpPWpGaD
Pemetrexed—DHFR—Disease—APC—ovarian cancer	2.61e-05	0.00026	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MAPK3—ovarian cancer	2.51e-05	0.000251	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—KRAS—ovarian cancer	2.48e-05	0.000247	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CA—ovarian cancer	2.45e-05	0.000244	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MYC—ovarian cancer	2.45e-05	0.000244	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CAV1—ovarian cancer	2.4e-05	0.000239	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CD—ovarian cancer	2.39e-05	0.000239	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MAPK1—ovarian cancer	2.39e-05	0.000238	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TP53—ovarian cancer	2.3e-05	0.000229	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CD—ovarian cancer	2.3e-05	0.000229	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CA—ovarian cancer	2.28e-05	0.000227	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CG—ovarian cancer	2.19e-05	0.000218	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—HRAS—ovarian cancer	2.11e-05	0.00021	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CAV1—ovarian cancer	2.1e-05	0.000209	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CB—ovarian cancer	2.09e-05	0.000208	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ERBB2—ovarian cancer	2.03e-05	0.000202	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—IL6—ovarian cancer	2.02e-05	0.000201	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TP53—ovarian cancer	2.01e-05	0.0002	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CB—ovarian cancer	2e-05	0.0002	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MTOR—ovarian cancer	2e-05	0.0002	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—AKT1—ovarian cancer	2e-05	0.000199	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CD—ovarian cancer	1.92e-05	0.000192	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CG—ovarian cancer	1.91e-05	0.00019	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CA—ovarian cancer	1.91e-05	0.00019	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN1B—ovarian cancer	1.88e-05	0.000187	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—AKT1—ovarian cancer	1.86e-05	0.000185	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTEN—ovarian cancer	1.8e-05	0.00018	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CTNNB1—ovarian cancer	1.78e-05	0.000177	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTEN—ovarian cancer	1.73e-05	0.000172	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CD—ovarian cancer	1.68e-05	0.000167	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CB—ovarian cancer	1.68e-05	0.000167	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—AKT1—ovarian cancer	1.56e-05	0.000155	CbGpPWpGaD
Pemetrexed—DHFR—Disease—STAT3—ovarian cancer	1.55e-05	0.000154	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NRAS—ovarian cancer	1.54e-05	0.000154	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MAPK3—ovarian cancer	1.48e-05	0.000147	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CB—ovarian cancer	1.46e-05	0.000146	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTEN—ovarian cancer	1.45e-05	0.000144	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MYC—ovarian cancer	1.44e-05	0.000143	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MAPK1—ovarian cancer	1.41e-05	0.00014	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EGFR—ovarian cancer	1.41e-05	0.00014	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KRAS—ovarian cancer	1.33e-05	0.000132	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CA—ovarian cancer	1.27e-05	0.000127	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTEN—ovarian cancer	1.26e-05	0.000126	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CA—ovarian cancer	1.22e-05	0.000122	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HRAS—ovarian cancer	1.13e-05	0.000113	CbGpPWpGaD
Pemetrexed—DHFR—Disease—IL6—ovarian cancer	1.08e-05	0.000108	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—AKT1—ovarian cancer	1.04e-05	0.000104	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CA—ovarian cancer	1.02e-05	0.000102	CbGpPWpGaD
Pemetrexed—DHFR—Disease—AKT1—ovarian cancer	9.97e-06	9.94e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CA—ovarian cancer	8.92e-06	8.89e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—AKT1—ovarian cancer	8.35e-06	8.32e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—AKT1—ovarian cancer	7.29e-06	7.26e-05	CbGpPWpGaD
